| |
| |
|
| Insider
Information: |
Coughlin Timothy P |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
190,353 |
|
|
Indirect Shares
|
62,390 |
|
|
| Direct
Value |
$19,505,789 |
|
|
|
Indirect Value
|
$210,841 |
|
|
| Total
Shares |
252,743 |
|
|
| Total
Value |
$19,716,630 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -74.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Chief Financial Officer |
2017-02-06 |
137,961 |
|
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2023-05-17 |
42,500 |
2015-03-31 |
0 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2022-06-09 |
9,892 |
2022-06-09 |
56,390 |
Premium* |
|
|
aTyr Pharma Inc |
LIFE |
Director |
2023-05-17 |
0 |
2023-05-17 |
6,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
57 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2006-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
228 |
|
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2015-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2016-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
22,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
24,500 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2018-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
27,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
29,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
32,000 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
35,000 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,681 |
59,071 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
38,000 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
9,892 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-05-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
6,000 |
6,000 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • – |
2023-05-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
0 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
42,500 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2010-01-12 |
4 |
AS |
$2.52 |
$21,951 |
D/D |
(8,697) |
54,427 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2014-12-19 |
4 |
OE |
$2.59 |
$25,900 |
D/D |
10,000 |
107,874 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2015-01-08 |
4 |
OE |
$2.59 |
$25,900 |
D/D |
10,000 |
107,874 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2009-01-13 |
4 |
AS |
$3.39 |
$28,648 |
D/D |
(8,463) |
22,574 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2010-03-01 |
4 |
AS |
$2.53 |
$31,972 |
D/D |
(12,650) |
75,110 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2014-01-10 |
4 |
AS |
$18.56 |
$32,480 |
D/D |
(1,750) |
97,874 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.81 |
$32,824 |
D/D |
(1,439) |
57,632 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2008-02-12 |
4 |
AS |
$4.96 |
$39,450 |
D/D |
(7,857) |
11,704 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
VP and Chief Financial Officer |
• – – |
2009-03-30 |
4 |
AS |
$3.43 |
$41,537 |
D/D |
(12,117) |
43,790 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Chief Financial Officer |
• – – |
2017-02-06 |
4 |
AS |
$43.14 |
$41,544 |
D/D |
(963) |
137,961 |
0 |
- |
|
57 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
